Blog

4

PharmaSecure at PatientSafe India in June ’16

PharmaSecure was proud to support PatientSafe India, held in Mumbai in June, focusing on tackling the drug counterfeiting challenge in India and beyond.  CEO Nakul Pasricha shared his views at the conference, highlighting the ways that anti-counterfeiting initiatives can be leveraged for patient engagement and adherence, turning a perceived problem into a business opportunity.

2

PharmaSecure participated at FIGH ‘16

The PharmaSecure team was invited to participate at the Financing & Innovation in Global Health Forum in Washington, D.C., held at the U.S. Institute for Peace in April 2016.  The forum focused on bridging the estimated $2.5 trillion annual funding gap in order to achieve the Sustainable Development Goals (SDGs).  Healthcare and technology innovations from around the world were featured as part of the Innovation Galaxy at the forum, one of which was PharmaSecure.  Nakul Pasricha, PharmaSecure CEO, participated in a panel discussion titled “Scaling Up Access to Medicines”, in which he shared his views on protecting supply chains against counterfeiting through technological solutions, political will, and strong enforcement.

3

2016-05-20

Dr. Reddy’s awards PharmaSecure for its Patient Adherence Programmes

PharmaSecure, a leading provider of anti-counterfeiting and patient adherence solutions was

awarded by Dr. Reddy’s at its 2016 MPOWER annual event for its ‘Patient Adherence

Programmes’.

Dr.Reddy’s hosted its annual brand event MPOWER to recognize the contributions of

outstanding individuals and partners over the Financial Year 2016. PharmaSecure was

recognized as a ‘Valuable Partner’ for its effort in the field of Patient Adherence.

PharmaSecure has been working with Dr.Reddy’s to provide patient adherence services for

select brands over the past few years.

Adherence is the degree to which a patient follows her treatment regimen. India faces a major

challenge of patient non-compliance as a large number of patients do not take their medicines

or treatment as prescribed. PharmaSecure employs its psConnect platform to address the

problem of non-adherence in order to improve health outcome in the country.

Dr. Reddy’s Laboratories Ltd. (NYSE: RDY) is an integrated pharmaceutical company, committed

to providing affordable and innovative medicines for healthier lives. Through its three

businesses – Pharmaceutical Services & Active Ingredients, Global Generics and Proprietary

Products – Dr. Reddy’s offers a portfolio of products and services including APIs, custom

pharmaceutical services, generics, biosimilars and differentiated formulations. Our major

therapeutic areas of focus are gastro-intestinal, cardiovascular, diabetology, oncology, pain

management and anti-infectives. Dr. Reddy’s operates in markets across the globe. Our major

markets include – USA, Russia & CIS and India.

stop TB Partnerhsip

PharmaSecure has joined the Stop TB Partnership, joining a group of 1300 partners working to transform the fight against tuberculosis

PharmaSecure, a leading provider of serialization, brand protection, and patient engagement solutions, is excited to announce that it has joined the Stop TB Partnership, a group of 1300 partners around the world working to transform the fight against tuberculosis.

Participating in this partnership adds PharmaSecure’s resources to the Stop TB Partnership campaign and furthers PharmaSecure’s efforts in improving public health outcomes.

PharmaSecure’s Public Health efforts combatting Tuberculosis (TB)

Despite global progress, the Stop TB Partnership reports that there are still more than 2 billion people infected with TB in the world and 9 million new cases every year, ultimately causing 1.5 million deaths annually.

India has a high TB burden and a majority of that problem exists in the private sector. According to the World Health Organization, there were an estimated 2.1 million cases of TB in India in 2013.

PharmaSecure has been working to introduce low cost scalable solutions that help identify TB patients and then help them to complete their TB treatment as prescribed by providing adherence interventions.

PharmaSecure is currently one of the recipients of the Grand Challenges in TB Control grant from the Bill & Melinda Gates Foundation and USAID, which is designed to fund novel solutions to improve the health outcomes of patients with TB.

Through this grant program, PharmaSecure enrolled TB patients in its psConnect™ patient engagement and management platform to help them complete their treatment regimen using customized reminders and incentives. Results from the first phase of this program showed that TB patients enrolled in the program had 60% greater reported adherence to the TB regimen than non-enrolled patients.

Fighting Tuberculosis through mobile health tools

Through PharmaSecure’s psConnect™ patient engagement platform, public health professionals can understand in almost real time the adherence of TB patients to their treatment and identify obstacles to treatment completion. This gives an accurate picture of treatment results and challenges faced by patients in their course of treatment which can be used to improve public health outcomes.

PharmaSecure’s CEO, Nakul Pasricha, commented, “We are excited to be joining The Stop TB Partnership and adding our efforts to the 1300 partners working to transform the fight against TB in more than 100 countries. PharmaSecure’s public health efforts are a core part of our company and we look forward to leveraging our innovative mobile health solutions to improve public health outcomes, particularly in emerging markets at risk from TB.”


 

About The Stop TB Partnership:

The Stop TB Partnership is leading the way to a world without tuberculosis (TB), a disease that is curable but still kills three people every minute. Founded in 2001, the Partnership’s mission is to serve every person who is vulnerable to TB and ensure that high-quality treatment is available to all who need it.

Together our 1300 partners are a collective force that is transforming the fight against TB in more than 100 countries. They include international and technical organizations, government programmes, research and funding agencies, foundations, NGOs, civil society and community groups and the private sector.

Email: communications@stoptb.org

About PharmaSecure:

PharmaSecure was founded in the United States in 2007 with a vision to protect medicines against counterfeiting by uniquely identifying each medicine pack sold. PharmaSecure and ProductSecure mobile technology solutions protect products across industries from counterfeiting while providing intelligence on their distribution, use in emerging markets, and improving engagement with consumers of those products.

To date, PharmaSecure has protected over 2.0 billion packages for 60+ companies through serialization for brand protection, regulatory compliance, consumer and patient engagement, and market intelligence. For more information please visit www.pharmasecure.com.

Fight the Fakes

PharmaSecure partners with Fight the Fakes Campaign, joining a group of leading public health organizations working to raise awareness about the dangers of fake medicines

PharmaSecure, a leading provider of serialization, brand protection, and patient engagement solutions, is excited to announce that it has joined as a Partner of Fight the Fakes, a campaign dedicated to raising awareness about the dangers of fake medicines. The campaign gives a voice to those who have been personally impacted by fake medicines and shares the stories of those working to put a stop to this threat to public health.

Fake medicines put patients and the general public at risk. Patients believe they are receiving genuine treatment, but instead they are getting potentially dangerous products that could increase resistance to real treatments, and cause further illness, disability or even death.

Fight the Fakes seeks to build a global movement of organizations and individuals who will shine light on the negative impact that fake medicines have on people around the globe and to reduce the negative consequences on individuals worldwide. Fight the Fakes partners endorse the campaign and share the belief that coordination among all actors involved in public health, and in particular in the manufacturing and distribution of medicines is vital to tackle this public health threat.

In order to encourage the collection and dissemination of individual stories, the Fight the Fakes website (www.fightthefakes.org) provides an effective platform for those who are impacted by fake medicines and helps to make their stories heard. The website also serves as a resource for those who want to take an active role in supporting the campaign’s effort by providing an outline of opportunities for action and collaboration and by sharing information tools.

How PharmaSecure will Support the Fight the Fakes Campaign

PharmaSecure will work with Fight the Fakes on a number of fronts, including collecting and sharing stories through its on-the ground presence in emerging countries where fake medicines are a significant threat including India and Nigeria. Together with Fight the Fakes partners, PharmaSecure will disseminate information about the real harm fake medicines have on individuals, provide resources to raise the profile of this silent killer, and outline opportunities for action at local level.

“PharmaSecure is excited to be partnering with Fight the Fakes to raise awareness about the dangers of fake medicines. Fake medicines are a dangerous and deadly industry, particularly in emerging markets, that put patients and the general public at risk. Increasing awareness and empowering consumers to identify fake medicines is integral to combating this threat to public health,” said Nakul Pasricha, CEO of PharmaSecure.

In addition to fighting fake medicines, PharmaSecure has made improving public health a focus through its work combatting tuberculosis (TB). PharmaSecure is currently one of the recipients of the Grand Challenges in TB Control grant from the Bill & Melinda Gates Foundation and USAID, which is designed to fund novel solutions to improve the health outcomes of patients with TB.

To date, PharmaSecure has provided IDs to more than 1.8B packages around the world and serves more than 15,000 patients daily through its patient engagement platform which has been proven to increase adherence rates to medicine treatments up to 60%.

About Fight the Fakes:

Fight the Fakes is a campaign that aims to raise awareness about the dangers of fake medicines. The campaign gives a voice to those who have been personally impacted and shares the stories of those working to put a stop to this threat to public health. It seeks to build a global movement of organizations and individuals who will shine light on the negative impact that fake medicines have on people around the globe and to reduce the negative consequences on individuals worldwide.

Fight the Fakes partners endorse the campaign and share the belief that coordination among all actors involved in the manufacturing and distribution of medicines is vital to tackle this public health threat. For more information please visit www.fightthefakes.org.

Email: info@fightthefakes.org

About PharmaSecure:

PharmaSecure was founded in the United States in 2007 with a vision to protect medicines against counterfeiting by uniquely identifying each medicine pack sold. PharmaSecure and ProductSecure mobile technology solutions protect products across industries from counterfeiting while providing intelligence on their distribution, use in emerging markets, and improving engagement with consumers of those products.

To date, PharmaSecure has protected over 1.8 billion packages for 60+ companies through serialization for brand protection, regulatory compliance, consumer and patient engagement, and market intelligence. For more information please visit www.pharmasecure.com.

Grand Challenge in TB Control

PharmaSecure advances to phase two of “The Grand Challenges in TB Control” program in India, sponsored by The Gates Foundation and USAID

Transforming healthcare delivery in emerging markets by tracking the distribution of medicines and understanding the behavior and outcomes of the patients who use them

New Delhi, India (August 10, 2015) – PharmaSecure, a leading global provider of brand protection and customer engagement solutions, has been one of four organizations selected to advance to phase two of “The Grand Challenges in TB Control” program, sponsored by the Gates Foundation and USAID, to find novel solutions to improve the health outcomes of patients with Tuberculosis (TB). Results from the first phase of the program in India showed that patients who were enrolled in PharmaSecure’s psConnect™ patient management platform had a 60% increase in reported adherence to the TB drug regimen over non-enrolled patients.In phase one of the program, PharmaSecure enrolled patients in their psConnect™ patient management and engagement platform to help TB patients complete their treatment regimen using customized reminders and incentives. Those patients who were enrolled in PharmaSecure’s psConnect™ patient management platform received either a reminder SMS, automated phone calls, or a direct call from a PharmaSecure patient liaison. A typical TB treatment regimen requires daily doses of antibiotics for 3-9 months and missed doses can lead to complications in treatment and may lead to drug resistance, risking lives and wasting public health funding. TB is second only to HIV/AIDS as the greatest killer worldwide due to a single infectious agent. In 2013, 9 million people fell ill with TB and 1.5 million died from the disease according to the World Health Organization. In India alone there were over 2 million incidences of TB in 2013 and an estimated 40% of the population is infected with TB bacteria, the vast majority of which is latent rather than active TB.

Phase two of the program will involve expanding the scope to specific geographies, to not only understand the impact on patient adherence, but also the drivers of adherence including the circumstances that a patient finds themselves in (e.g., no access to running water) and the challenges they face in adhering to treatment (e.g., lack of time).

About PharmaSecure

PharmaSecure was founded in the United States in 2007 with a vision to protect medicines against counterfeiting by uniquely identifying each medicine pack sold. PharmaSecure and ProductSecure mobile technology solutions protect products across industries from counterfeiting while providing intelligence on their distribution, use in emerging markets, and improving engagement with consumers of those products. Till date, PharmaSecure has protected over 1.5 billion packages for 50 companies through serialization for brand protection, regulatory compliance, patient engagement and market intelligence.

About “The Grand Challenges in TB Control” Program

The Grand Challenges in TB Control (GC-TBC) is an initiative to encourage and nurture innovations that will help alleviate the problem of TB in India. IKP Knowledge Park (IKP), the United States Agency for International Development (USAID), the Biotechnology Industry Research Assistance Council (BIRAC), and the Bill and Melinda Gates Foundation (BMGF) are working together to identify, fund, and nurture technology driven solutions that will assist TB control.

SFM Workhsop June 2015

PharmaSecure CEO attends Workshop on Stolen and Falsified Medicines in London

PharmaSecure CEO Nakul Pasricha attended a Workshop on Stolen and Falsified Medicines, hosted jointly by KPMG and The Global Fund to fight AIDS, Tuberculosis and Malaria, held in London on 24th and 25th June, 2015.
The workshop had attendees representing global pharma companies, solution providers as well as experts in the field of drug counterfeiting. The agenda focused on coming up with practical, implementable ways in which pharma companies, solution providers and the Global Fund can join hands to tackle the problem.Mr. Pasricha gave a presentation highlighting the advances made by PharmaSecure in terms of implementing solutions that can satisfy global anti-counterfeiting regulations while delivering value to brand owners through increased patient adherence. Mr. Pasricha stressed that the best anti-counterfeiting measure is an empowered, informed and engaged patient.The workshop resulted in concrete plans that will be implemented over the coming months.
global_health

PharmaSecure at Prince Mahidol Award Conference

PharmaSecure CEO Nathan Sigworth spoke on the Governance by Market Forces Panel at the Prince Mahidol Award Conference in Bangkok, Thailand. The panel was led by Andreas Seiter of the World Bank and Patricia Moser of the Asian Development Bank. Two themes from the session: (1) Price discovery based on better market intelligence can align the interests of public health and pharmaceutical companies in increasing patient access to quality healthcare. (2) New technologies need to be adopted at scale that change the way governments do public health: we need to move from having a separate physical infrastructure to utilizing information infrastructure that allows public health to leverage the efficiencies of private sector distribution.
Sigworth’s presentation focused on how pharmaceutical companies are using serialization to understand the behavior of individual patients over time including how much pricing is a factor in the decisions they make.  Also on the panel were Olivier Basenya from the Ministry of Health of Burundi, Clinton de Souza from Imperial Logistics, Thalami Mbatha from University Research South Africa and Richard Bergstrom from the EFPIA.
About Us

Founded with a vision to protect medicines against counterfeiting, PharmaSecure™ solutions protect products across industries, help manufacturers meet global regulatory serialization requirements, and enable innovative patient and consumer engagement programs. learn more...

Get In Touch
PharmaSecure India - Sales
505, 5th Floor, Timmy Arcade,
Makwana Road, Marol,
Andheri (East) Mumbai – 400059 (India)
P:+91 22 6755 6011
PharmaSecure Inc.
@ The Centre for Social Innovation
Suite 325-254
601 West 26th Street
New York, New York 10001, USA
P:+1 866-350-4450 ext.804